Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
$10.50
$10.46
$2.00
$10.50
$231.40M-4.81142,261 shsN/A
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
$8.12
-0.1%
$6.15
$3.96
$8.56
$224.27M0.3296,642 shs63,495 shs
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
$21.55
$21.50
$2.31
$21.60
$1.83B-0.691.69 million shsN/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
$4.01
-1.4%
$3.94
$3.36
$12.70
$161.70M1.1520,954 shs1,139 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
-0.12%-2.05%+35.11%+18.20%+15.50%
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
0.00%0.00%0.00%0.00%+0.47%
Molecular Partners AG stock logo
MOLN
Molecular Partners
+0.15%+1.14%-1.84%-18.00%+5.39%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
2.1372 of 5 stars
3.60.00.00.03.33.30.0
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
2.5683 of 5 stars
3.84.00.00.02.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
0.00
N/AN/AN/A
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
3.25
Buy$13.0060.10% Upside
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
0.00
N/AN/AN/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
3.50
Strong Buy$12.00199.63% Upside

Current Analyst Ratings Breakdown

Latest CMPI, MOLN, FUSN, and FENC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
5/14/2025
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $13.00
3/11/2025
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/11/2025
Molecular Partners AG stock logo
MOLN
Molecular Partners
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
3/10/2025
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$13.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/A$2.50 per shareN/A
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
$30.91M7.25N/AN/A($0.43) per share-18.88
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
$2.07M885.53N/AN/A$3.07 per share7.02
Molecular Partners AG stock logo
MOLN
Molecular Partners
$2.23M72.45N/AN/A$5.41 per share0.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/A
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
-$16.05M-$0.51N/AN/AN/A-2.30%-53.38%-2.08%8/12/2025 (Estimated)
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
-$94.90M-$1.42N/AN/AN/A-4,136.55%-48.74%-36.87%N/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
-$69.04M-$1.92N/AN/AN/A-1,043.01%-39.31%-35.46%N/A

Latest CMPI, MOLN, FUSN, and FENC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Molecular Partners AG stock logo
MOLN
Molecular Partners
-$0.3855-$0.50-$0.1145-$0.50N/AN/A
5/13/2025Q1 2025
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million
3/6/2025H2 2024
Molecular Partners AG stock logo
MOLN
Molecular Partners
-$0.45-$0.34+$0.11-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/AN/AN/AN/AN/A
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
N/AN/AN/AN/AN/A
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
N/AN/AN/AN/AN/A
Molecular Partners AG stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
N/A
5.20
5.20
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
N/A
7.80
7.64
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
0.21
10.64
10.64
Molecular Partners AG stock logo
MOLN
Molecular Partners
N/A
14.33
14.33

Institutional Ownership

CompanyInstitutional Ownership
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
74.56%
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
55.51%
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
72.85%
Molecular Partners AG stock logo
MOLN
Molecular Partners
26.55%
CompanyEmployeesShares OutstandingFree FloatOptionable
Checkmate Pharmaceuticals, Inc. stock logo
CMPI
Checkmate Pharmaceuticals
2822.04 million8.24 millionNot Optionable
Fennec Pharmaceuticals Inc stock logo
FENC
Fennec Pharmaceuticals
N/A27.62 million24.54 millionOptionable
Fusion Pharmaceuticals Inc. stock logo
FUSN
Fusion Pharmaceuticals
10185.06 million78.47 millionOptionable
Molecular Partners AG stock logo
MOLN
Molecular Partners
18040.38 million37.97 millionNot Optionable

Recent News About These Companies

Q2 Earnings Estimate for MOLN Issued By Leerink Partnrs
Molecular Partners AG stock logo
Brokers Offer Predictions for MOLN Q2 Earnings
Molecular Partners (MOLN) Initiated with a Buy at LifeSci Capital
Molecular Partners initiated with an Outperform at LifeSci Capital

New MarketBeat Followers Over Time

Media Sentiment Over Time

Checkmate Pharmaceuticals stock logo

Checkmate Pharmaceuticals NASDAQ:CMPI

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fennec Pharmaceuticals stock logo

Fennec Pharmaceuticals NASDAQ:FENC

$8.12 -0.01 (-0.12%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$8.13 +0.01 (+0.12%)
As of 05/28/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Fusion Pharmaceuticals stock logo

Fusion Pharmaceuticals NASDAQ:FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$4.00 -0.06 (-1.35%)
As of 05/28/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.